FdaApplication
NDA 050794
Identifiers
- fda_app_no: NDA050794
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL-MYERS SQUIBB CO |
| application_type | NDA |
| approval_date | 2004-05-19 |
Revenue by product
VIDAZA
| Period | Revenue |
|---|---|
| Q3 2021 | $36.0M |
| Q2 2021 | $45.0M |
| Q1 2021 | $54.0M |
| Q4 2020 | $65.0M |
| Q3 2020 | $106.0M |
| Q2 2020 | $126.0M |
| Q1 2020 | $158.0M |
| Q4 2019 | $58.0M |
| Q3 2019 | $0.0M |
| Q2 2019 | $0.0M |
| Q1 2019 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VIDAZA | AZACITIDINE | 100MG/VIAL | POWDER;INTRAVENOUS, SUBCUTANEOUS |
1 product